Immunome Inc Financials
Immunome Inc (IMNM) reported $6.9M in revenue for fiscal year 2025, down 23.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Investor funding, not customer revenue, is carrying a research-heavy business whose cash burn still dwarfs sales.
FY2025 cash jumped to$653.5M from$143.4M , but the increase was driven by financing inflows, not by the business producing cash. Operating cash burn deepened to-$190.9M while revenue slipped to$6.9M , so the stronger balance sheet reflects fundraising outpacing cash use, not a commercial engine that has started funding itself.
This is a development-stage cost structure: R&D reached
Liquidity is now unusually high relative to obligations, with cash of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Immunome Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Immunome Inc scores 38.31, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.2B) relative to total liabilities ($48.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Immunome Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Immunome Inc reported a net loss of $212.4M while operations used $190.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Immunome Inc reported an operating loss of $224.1M against $11.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Immunome Inc generated $6.9M in revenue in fiscal year 2025. This represents a decrease of 23.2% from the prior year.
Immunome Inc's EBITDA was -$221.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.1% from the prior year.
Immunome Inc reported -$212.4M in net income in fiscal year 2025. This represents an increase of 27.5% from the prior year.
Immunome Inc earned -$2.43 per diluted share (EPS) in fiscal year 2025. This represents an increase of 51.4% from the prior year.
Cash & Balance Sheet
Immunome Inc recorded an outflow of $200.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 70.1% from the prior year.
Immunome Inc held $653.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Immunome Inc's ROE was -33.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 128.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Immunome Inc invested $177.3M in research and development in fiscal year 2025. This represents an increase of 36.9% from the prior year.
Immunome Inc invested $9.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 35.0% from the prior year.
Not reported for fiscal year 2025.
IMNM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $6.9M-23.2% | $9.0M-35.5% | $14.0M | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $177.3M+36.9% | $129.5M+461.1% | $23.1M-0.8% | $23.3M+64.9% | $14.1M+88.5% | $7.5M-15.2% | $8.8M |
| SG&A Expenses | N/A | $43.8M+32.8% | $33.0M+67.7% | $19.7M+44.2% | $13.6M+22.9% | $11.1M+132.3% | $4.8M+213.1% | $1.5M |
| Operating Income | N/A | -$224.1M+26.7% | -$305.8M-179.2% | -$109.5M-196.8% | -$36.9M-46.4% | -$25.2M-105.6% | -$12.3M-18.5% | -$10.3M |
| Interest Expense | N/A | $11.7M-8.7% | $12.8M+371.3% | $2.7M+54380.0% | $5K+150.0% | -$10K-147.6% | $21K-54.3% | $46K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$212.4M+27.5% | -$293.0M-174.3% | -$106.8M-189.5% | -$36.9M-49.3% | -$24.7M-38.5% | -$17.8M-70.8% | -$10.4M |
| EPS (Diluted) | — | -$2.43+51.4% | -$5.00 | -$5.38 | -$3.09-44.4% | -$2.14 | -$5.26 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IMNM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $683.2M+184.4% | $240.2M+61.7% | $148.5M+517.7% | $24.0M-58.5% | $57.9M+30.1% | $44.5M+779.9% | $5.1M |
| Current Assets | $660.8M+198.5% | $221.3M+53.0% | $144.7M+538.9% | $22.6M-60.0% | $56.6M+32.0% | $42.9M+1273.9% | $3.1M |
| Cash & Equivalents | $653.5M+355.9% | $143.4M+45.3% | $98.7M+385.6% | $20.3M-58.7% | $49.2M+23.8% | $39.8M+1463.7% | $2.5M |
| Total Liabilities | $48.8M-17.3% | $59.1M+106.1% | $28.7M+287.6% | $7.4M-24.1% | $9.7M+206.3% | $3.2M-92.2% | $40.7M |
| Current Liabilities | $45.0M-17.2% | $54.3M+148.8% | $21.8M+197.8% | $7.3M-24.6% | $9.7M+220.2% | $3.0M+82.5% | $1.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $134K | N/A |
| Total Equity | $634.3M+250.1% | $181.2M+51.1% | $119.9M+619.9% | $16.7M-65.4% | $48.2M+16.5% | $41.3M+216.0% | -$35.6M |
| Retained Earnings | -$728.2M-41.2% | -$515.8M-131.5% | -$222.8M-92.1% | -$116.0M-46.6% | -$79.1M-45.4% | -$54.4M-48.8% | -$36.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
IMNM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$208.8M | -$190.9M-72.3% | -$110.8M-1364.0% | -$7.6M+73.6% | -$28.7M-57.4% | -$18.2M-50.2% | -$12.1M-26.4% | -$9.6M |
| Capital Expenditures | $10.3M | $9.7M+35.0% | $7.2M+763.2% | $831K+235.1% | $248K+213.9% | $79K-86.5% | $586K+151.5% | $233K |
| Free Cash Flow | -$219.1M | -$200.6M-70.1% | -$118.0M-1304.5% | -$8.4M+71.0% | -$28.9M-58.1% | -$18.3M-43.9% | -$12.7M-29.4% | -$9.8M |
| Investing Cash Flow | -$196.5M | $60.8M+171.5% | -$85.1M-179.0% | -$30.5M-12191.9% | -$248K-213.9% | -$79K+86.5% | -$586K-151.5% | -$233K |
| Financing Cash Flow | $479.1M | $640.4M+166.2% | $240.5M+106.6% | $116.4M+363675.0% | $32K-99.9% | $27.8M-44.4% | $49.9M+363.6% | $10.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IMNM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -3228.8% | -3382.4% | -781.4% | N/A | N/A | N/A | N/A |
| Net Margin | -3060.0% | -3240.4% | -761.9% | N/A | N/A | N/A | N/A |
| Return on Equity | -33.5%+128.2pp | -161.7%-72.6pp | -89.1%+132.5pp | -221.6%-170.3pp | -51.3%-8.1pp | -43.1% | N/A |
| Return on Assets | -31.1%+90.9pp | -122.0%-50.1pp | -71.9%+81.5pp | -153.4%-110.8pp | -42.7%-2.6pp | -40.1%+166.3pp | -206.4% |
| Current Ratio | 14.69+10.6x | 4.08-2.6x | 6.63+3.5x | 3.09-2.7x | 5.82-8.3x | 14.12+12.2x | 1.88 |
| Debt-to-Equity | 0.08-0.2x | 0.33+0.1x | 0.24-0.2x | 0.44+0.2x | 0.20+0.2x | 0.00 | N/A |
| FCF Margin | -2890.1% | -1304.8% | -59.9% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Immunome Inc Ranks
Frequently Asked Questions
What is Immunome Inc's annual revenue?
Immunome Inc (IMNM) reported $6.9M in total revenue for fiscal year 2025. This represents a -23.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Immunome Inc's revenue growing?
Immunome Inc (IMNM) revenue declined by 23.2% year-over-year, from $9.0M to $6.9M in fiscal year 2025.
Is Immunome Inc profitable?
No, Immunome Inc (IMNM) reported a net income of -$212.4M in fiscal year 2025.
What is Immunome Inc's EBITDA?
Immunome Inc (IMNM) had EBITDA of -$221.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immunome Inc's return on equity (ROE)?
Immunome Inc (IMNM) has a return on equity of -33.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immunome Inc's free cash flow?
Immunome Inc (IMNM) recorded an outflow of $200.6M in free cash flow during fiscal year 2025. This represents a -70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immunome Inc's operating cash flow?
Immunome Inc (IMNM) recorded an outflow of $190.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immunome Inc's total assets?
Immunome Inc (IMNM) had $683.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immunome Inc's capital expenditures?
Immunome Inc (IMNM) invested $9.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immunome Inc spend on research and development?
Immunome Inc (IMNM) invested $177.3M in research and development during fiscal year 2025.
What is Immunome Inc's current ratio?
Immunome Inc (IMNM) had a current ratio of 14.69 as of fiscal year 2025, which is generally considered healthy.
What is Immunome Inc's debt-to-equity ratio?
Immunome Inc (IMNM) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Immunome Inc's return on assets (ROA)?
Immunome Inc (IMNM) had a return on assets of -31.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immunome Inc's cash runway?
Based on fiscal year 2025 data, Immunome Inc (IMNM) had $653.5M in cash against an annual operating cash burn of $190.9M. This gives an estimated cash runway of approximately 41 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Immunome Inc's Altman Z-Score?
Immunome Inc (IMNM) has an Altman Z-Score of 38.31, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Immunome Inc's Piotroski F-Score?
Immunome Inc (IMNM) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immunome Inc's earnings high quality?
Immunome Inc (IMNM) reported a net loss of $212.4M while operations used $190.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Immunome Inc cover its interest payments?
Immunome Inc (IMNM) reported an operating loss of $224.1M against $11.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Immunome Inc?
Immunome Inc (IMNM) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.